The Next Wave in Adaptive Biomedical Innovation:
Advancing Platform Trials into End to End Rapid Learning Systems

From siloed to ecosystem-driven innovation

Applying adaptive biomedical innovation

Scaling platform clinical trials

Connecting pre- and post-market learning

Designing disease ecosystems

Driving sustainable, patient-centered innovation

December 12–13, 2017
Massachusetts Institute of Technology

Register now

Early Bird registration and special discounts
Register now for the Early Bird rate, which expires on November 12. NEWDIGS members, as well as faculty and students from any academic organization, are eligible for special discounts—just email newdigs@mit.edu for your code.

Breakthroughs in biomedical science are making transformative, even curative, therapies possible. But the healthcare system—patients, caregivers, regulators, payors, developers, and providers—is struggling to make them successful and sustainable.

We need to redesign the healthcare innovation system—together—to accelerate patient-centered drug development in ways that work for all stakeholders. Join other thought leaders at the Next Wave Forum and help to shape an evolving vision, and draw the roadmap, for a better system.

Join us

Patient advocates • Payors • Regulators • Industry • Clinicians • Academia • Investors

Featuring


  • Janet Woodcock, MD
    Director, Center for Drug Evaluation and Research at FDA

  • Robert Califf, MD
    Duke Clinical Research Institute & former Commissioner, FDA

  • Laura Esserman, MD, MBA
    Director, UCSF Carol Franc Buck Breast Care Center

  • Jonathan Gruber, PhD
    Ford Professor of Economics, MIT

  • Trent Haywood, MD, JD
    Chief Medical Officer, Office of Clinical Affairs, Blue Cross Blue Shield Association

  • Sandy Pentland, PhD
    Director, MIT Human Dynamics Laboratory

  • Sebastian Schneeweiss, MD, ScD
    Professor of Medicine and Epidemiology, Harvard Medical School

  • Marcus Wilson, PharmD
    Co-founder and President, HealthCore

Additional esteemed speakers


  • Brian Alexander, MD, MPH
    Disease Center Leader, Dana-Farber Cancer Institute

  • Derek C. Angus, MD, MPH, FRCP
    Chair, Department of Critical Care Medicine, University of Pittsburgh

  • Naomi Aronson, PhD
    Executive Director of Clinical Evaluation, Innovation, and Policy, Blue Cross and Blue Shield Association

  • Anna D. Barker, PhD
    Founding Director, National Biomarker Development Alliance

  • Don Berwick, MD, MPP
    President Emeritus, Institute for Healthcare Improvement

  • Nick Crabb, PhD
    Programme Director, Scientific Affairs at NICE

  • Edward Connor, MD, MBE, FAAP
    Executive Director and Scientific Lead, Pediatric Trials Consortium, Critical Path Institute

  • Michael A. Cusumano, PhD
    Sloan Management Review Distinguished Professor of Management, MIT

  • Jonathan M. Davis, MD
    Director of the CTSA Trial Innovation Network Center at the CTSA Hub
    Tufts CTSI; Floating Hospital for Children at Tufts Medical Center

  • Kourtney Davis, PhD, MSPH
    Global Head of Real World Data and Analytics, GlaxoSmithKline Pharmaceuticals

  • Anne-Virginie Eggimann, MSc
    Vice President, Regulatory Science, bluebird bio, Inc.

  • Hans-Georg Eichler, MD, MSc
    Senior Medical Officer, European Medicines Agency

  • John Ferguson, MD
    SVP, Distinguished Fellow, Shire

  • Keith T. Flaherty, MD
    Director of Developmental Therapeutics, Massachusetts General Hospital Cancer Center

  • R. John Glasspool
    Financing and Reimbursement of Cures in the US (FoCUS) Project Senior Advisor, CBI, MIT

  • Gigi Hirsch, MD
    Executive Director, Center for Biomedical Innovation, MIT

  • Peter Kolchinsky, PhD
    Portfolio Manager & Managing Director, RA Capital Management, LLC

  • Marina Kozak, PhD
    Project Officer, OS/ASPR/BARDA, U.S. Department of Health and Human Services

  • Denis Lacombe, MD, MSc
    Director General, EORTC

  • Kay Larholt, ScD
    Director of Integrated Knowledge Solutions, WISDOM Program, CBI, MIT

  • Laurice Levine, MA
    Independent Medical Consultant and Patient Advocate

  • Robyn Lim, PhD
    Senior Science Advisor, Office of Legislative and Regulatory Modernization, Health Canada

  • Newell McElwee, PharmD, MSPH
    Vice President, Health Economics and Outcomes Research, Boehringer-Ingelheim

  • Carole Mitnick, ScD
    Associate Professor of Global Health and Social Medicine, Harvard Medical School

  • Jane Perlmutter, PhD, MBA
    President and Founder, Gemini Group

  • Eleanor Perfetto, PhD, MS
    Professor of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy

  • Edmund Pezalla, MD, MPH
    Independent consultant; formerly Aetna

  • William B Rouse, PhD
    Alexander Crombie Humphreys Chair in Economics of Engineering, Stevens Institute of Technology

  • Eric Rubin, MD
    Vice President, Global Clinical Oncology, Merck & Co., Inc.

  • Susan Schaeffer
    Editor, BioCentury Publications

  • William E. Smoyer, MD
    Director, Center for Clinical and Translational Research, Nationwide Children’s Hospital

  • Mark Trusheim, MS
    President, Co-Bio Consulting

  • Luc Truyen, MD, PhD
    Global Head, Development and External Affairs, Neuroscience, The Janssen Pharmaceutical Companies

Including senior thought leaders from


Agenda

Day 1 morning:
Vision, Strategy, Evolution

Welcome and introduction

Panel
ABI: A vision for sustainable, patient-centered drug development, access, and value

Janet Woodcock
Roadmap to the future: From platform trials to disease-focused innovation ecosystems

Fireside Chat with Laura Esserman
Evolution in action: The iSPY story

Michael Cusumano
Outside-in learning: Insights from the evolution of industry platforms in other commercial verticals

Day 1 afternoon:
Platform trials

Panel
Advancing oncology platform trials

Panel
Translational system innovation: Platforms beyond oncology

Panel
Stakeholder perspectives on platform trials

Anna Barker
Evolution of Platform Trials: Lessons Learned So Far

Reception and poster session
Call for Poster Abstracts now open




Day 2 morning:
Data and evidence across the lifecycle

Welcome and introduction

Fireside Chat: Rob Califf & Trent Haywood
Bridging the chasm: Connecting pre- and post-market learning

Panel
Evidence Planning in Adaptive Biomedical Innovation: Field Observations

Panel
Driving Value for Patients from Real World Evidence: Snapshots of Evolving Ecosystems

Sandy Pentland
Can technology enable data sharing, integration, and trust?

Day 2 afternoon:
From siloed to ecosystem-driven innovation

Panel
Ecosystem-Enabled Innovation: Insights from the International Neonatal Consortium

Mark Trusheim
Advancing adaptive biomedical innovation: Designing disease ecosystems

William Rouse
Innovation in Fragmented Health Ecosystems

Panel
Evolving the global ecosystem: The Adaptive Biomedical Innovation Game

Jon Gruber
The political context for biomedical and healthcare innovation

Don Berwick
Driving continuous improvement across the system

Gigi Hirsch
Action Plan

Cutting-edge thinking: References

Woodcock, J, LaVange, L. 
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
The New England Journal of Medicine. 2017;377:62-70.

Hirsch G, Trusheim M, Cobbs E, Bala M, et al.
Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need
Clinical Pharmacology & Therapeutics, special issue on Adaptive Biomedical Innovation, published 14 November 2016 DOI:10.1002

Trusheim M, Shrier A, Antonijevic Z, Beckman R, et al.
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
Clinical Pharmacology & Therapeutics, special issue on Adaptive Biomedical Innovation, published 14 November 2016 DOI:10.1002

Califf R, Sherman R, Slavitt A.
Knowing When and How to Use Medical Products
JAMA. 2016;316(23):2485-2486. doi:10.1001/ jama.2016.16734

Loehrer S, Feeley D, Berwick D.
10 New Rules to Accelerate Healthcare Redesign
Healthcare Executive. 2015 Nov;30(6):66-69.

 

Details and Registration

The Next Wave in Adaptive Biomedical Innovation:
Advancing Platform Trials into End-to-End Rapid Learning Systems

December 12–13, 2017
Boston Marriott Cambridge
Cambridge, Massachusetts

Register now

Early Bird registration and special discounts
Register now for the Early Bird rate, which expires on November 12. NEWDIGS members, as well as faculty and students from any academic organization, are eligible for special discounts—just email newdigs@mit.edu for your code.

Sponsored by

Sector leader
and

Interested in demonstrating your organization’s leadership in biomedical innovation?
Check out Sponsorship opportunities or write to Deborah Young

Hosted by the MIT Center for Biomedical Innovation

The MIT Center for Biomedical Innovation integrates the Institute’s technical, scientific, and management expertise to solve complex biopharmaceutical challenges and improve the impact of biomedical innovation on society.

Cross-stakeholder collaboration drives CBI activity. Cutting-edge MIT research is complemented by expertise from industry, public agencies, and patient advocacy to develop scalable and sustainable solutions for problems in biopharmaceutical r&d, manufacturing, safety, and financing.

The Center advances practice through new knowledge and through real-world initiatives like NEW Drug Development ParaDIGmS (NEWDIGS) and The Biomanufacturing Project (BioMAN). Altogether, these activities bring parties together for mutual advantage and create system-scale healthcare impact.